News & Updates
Showing Multidisciplinary articles
Showing

STRIDE regimen boosts OS in unresectable HCC
The addition of tremelimumab to durvalumab (STRIDE regimen) in the first-line setting improved overall survival (OS) compared with sorafenib in patients with advanced unresectable hepatocellular carcinoma (HCC), according to results of the phase III HIMALAYA trial.

Sarcoidosis patients at risk of haematologic, nonmelanoma skin cancers
Sarcoidosis patients with biopsy-verified non-necrotizing granulomatous inflammation are at greater risk of haematologic cancers and nonmelanoma skin cancer (NMSC) in the long term than the general population, a study has found.

Dual inhibition of LAG-3, PD-1: a new therapeutic target for advanced melanoma?
In the phase II/III RELATIVITY-047 trial evaluating dual checkpoint inhibition for advanced melanoma, a new fixed-dose combination comprising the LAG-3 inhibitor relatlimab and the PD-1 inhibitor nivolumab fared better than nivolumab monotherapy.

Hypertension in pregnancy ups risk of poor delivery, infant outcomes
Hypertensive disorders in pregnancy seem to aggravate the risk of premature delivery and intrauterine growth retardation, reports a recent study. Consequentially, the delivered infants may be more likely to sustain injuries to the cardiovascular and endocrine system and suffer from neurodevelopmental delays.



